PGIM Custom Harvest’s Alexion Pharmaceuticals ALXN Stock Holding History

PGIM Custom Harvest’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,230	Closed	-$226K	–	250
2021 Q2	$226K	Buy	+1,230	New	+$211K	0.04%	162

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

PGIM Custom Harvest's ALXN Position: Q3 2021 in Review

PGIM Custom Harvest sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,230 shares — an estimated $226K sold.

PGIM Custom Harvest first reported a position in ALXN in Q2 2021 and held it in 1 quarter. The position peaked at $226K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

PGIM Custom Harvest reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
PGIM Custom Harvest sold 1,230 Alexion Pharmaceuticals shares in Q3 2021, an estimated $226K.
PGIM Custom Harvest first reported a position in Alexion Pharmaceuticals in Q2 2021 and held it in 1 quarter.
PGIM Custom Harvest's Alexion Pharmaceuticals position peaked at $226K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on PGIM Custom Harvest's 13F filing for Q3 2021, filed 12 Nov 2021.